Coutanceau Emmanuelle, Decalf Jeremie, Martino Angelo, Babon Aurélie, Winter Nathalie, Cole Stewart T, Albert Matthew L, Demangel Caroline
Unité de Génétique Moléculaire Bactérienne, Genomes and Genetics Department, Institut Pasteur, 75724 Paris, Cedex 15, France.
J Exp Med. 2007 Jun 11;204(6):1395-403. doi: 10.1084/jem.20070234. Epub 2007 May 21.
Mycolactone is a polyketide toxin produced by Mycobacterium ulcerans (Mu), the causative agent of the skin disease Buruli ulcer (BU). Surprisingly, infected tissues lack inflammatory infiltrates. Structural similarities between mycolactone and immunosuppressive agents led us to investigate the immunomodulatory properties of mycolactone on dendritic cells (DCs), the key initiators and regulators of immune responses. At noncytotoxic concentrations, phenotypic and functional maturation of both mouse and human DCs was inhibited by mycolactone. Notably, mycolactone blocked the emigration of mouse-skin DCs to draining lymph nodes, as well as their maturation in vivo. In human peripheral blood-derived DCs, mycolactone inhibited the ability to activate allogeneic T cell priming and to produce inflammatory molecules. Interestingly, production of the cytokines interleukin (IL) 12, tumor necrosis factor alpha, and IL-6 was only marginally affected, whereas production of the chemokines macrophage inflammatory protein (MIP) 1alpha, MIP-1beta, regulated on activation, normal T cell expressed and secreted, interferon gamma-inducible protein 10, and monocyte chemoattractant protein 1 was abolished at nanomolar concentrations. Importantly, mycolactone endogenously expressed by Mu mediated similar inhibitory effects on beta-chemokine production by DCs. In accordance with the histopathological features of BUs, our results suggest that bacterial production of mycolactone may limit both the initiation of primary immune responses and the recruitment of inflammatory cells to the infection site. Moreover, they highlight a potential interest in mycolactone as a novel immunosuppressive agent.
分枝杆菌内酯是由溃疡分枝杆菌(Mu)产生的一种聚酮化合物毒素,Mu是皮肤疾病布氏杆菌病(BU)的病原体。令人惊讶的是,受感染的组织缺乏炎性浸润。分枝杆菌内酯与免疫抑制剂之间的结构相似性促使我们研究分枝杆菌内酯对树突状细胞(DCs)的免疫调节特性,DCs是免疫反应的关键启动者和调节者。在无细胞毒性浓度下,分枝杆菌内酯抑制了小鼠和人类DCs的表型和功能成熟。值得注意的是,分枝杆菌内酯阻止了小鼠皮肤DCs迁移至引流淋巴结,以及它们在体内的成熟。在人类外周血来源的DCs中,分枝杆菌内酯抑制了激活同种异体T细胞启动和产生炎性分子的能力。有趣的是,细胞因子白细胞介素(IL)-12、肿瘤坏死因子α和IL-6的产生仅受到轻微影响,而趋化因子巨噬细胞炎性蛋白(MIP)-1α、MIP-1β、激活调节正常T细胞表达和分泌因子、干扰素γ诱导蛋白10和单核细胞趋化蛋白1的产生在纳摩尔浓度时被消除。重要的是,Mu内源性表达的分枝杆菌内酯对DCs产生β趋化因子具有类似的抑制作用。根据BU的组织病理学特征,我们的结果表明,细菌产生的分枝杆菌内酯可能会限制原发性免疫反应的启动以及炎性细胞向感染部位的募集。此外,这些结果凸显了分枝杆菌内酯作为一种新型免疫抑制剂的潜在价值。